Tibulizumab clinical trials
Also written LY3090106.
How each study uses tibulizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2013 (1)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2018 | 1 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Eli Lilly and Company (3) · Zura Bio Inc (1) · Matthew C. Baker (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test tibulizumab.
- May 2027Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)Phase 2 · Zura Bio Inc
Studies
Open first, then newest update. How each study uses tibulizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)Active, not recruitingPhase 2Zura Bio IncNCT06843239Written as Tibulizumab
- BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's SyndromeWithdrawnPhase 2/3Matthew C. BakerNCT04563195Written as tibulizumab (LY3090106)
- A Study of LY3090106 in Japanese and Caucasian Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03736772Written as LY3090106
- A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)CompletedPhase 1Eli Lilly and CompanyNCT02614716Written as LY3090106
- A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)CompletedPhase 1Eli Lilly and CompanyNCT01925157Written as LY3090106 - SQ
Codes
What other systems call tibulizumab · ClinicalTrials.gg INT014776
- UNII (FDA) 42HQ15W1ZFTIBULIZUMABOne source FDA
- NCI Thesaurus C152608TibulizumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 42HQ15W1ZF | TIBULIZUMAB | One source FDA |
| NCI Thesaurus | C152608 | Tibulizumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.